Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Трансплантация сердца, наличие трансплантированного сердца, отмирание и отторжение трансплантата сердца

Список литературы

  1. Maddox T.M., Januzzi J.L., Allen L.A., et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021; 77 (6): 772–810.
  2. McDonagh T.A., Metra M., Adamo M., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2021; 42 (36): 3599–3726. 
  3. Готье С.В., Шевченко А.О., Кормер А.Я, Попцов В.Н., Саитгареев Р. Ш., Шумаков Д.В., Захаревич В.М. Три десятилетия трансплантации сердца в ФНЦ ТИО имени академика В.И. Шумакова: отдаленные результаты. Вестник трансплантологии и искусственных органов. 2015. Т. 15. № 2. С. 70-73.
  4. Lund et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report—2015. J Heart Lung Transplant 2015; 34:1244–1254.
  5. Готье С.В., Шевченко А.О., Попцов В.Н., Саитгареев Р.Ш., Захаревич В.М., Шумаков Д.В., Акопов Г.А. Опыт 800 трансплантаций сердца в НМИЦ трансплантологии и искусственных органов им. акад. В.И. Шумакова. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № S. С. 52-53.
  6. Gautier SV, Shevchenko AO, et al. Thirty-Year Dynamics of Survival among Heart Recipients: A Single Center Russian Experience. Transplantation. 2018; 102: S827. DOI: 10.1097/01.tp.0000543875.50643.83.
  7. Клинические рекомендации «Хроническая сердечная недостаточность», одобрены Научно-практическим Советом Минздрава РФ в 2020. https://cr.minzdrav.gov.ru/schema/156_1#doc_a1
  8. Готье С.В., Шевченко А.О., Кормер А.Я., Попцов В.Н., Шевченко О.П. Перспективы улучшения отдаленных результатов трансплантации сердца. Вестник трансплантологии и искусственных органов. 2014. Т. XVI. № 3. С. 23-30.
  9. Готье C.В., Захаревич В.М., Халилулин Т.А, Шевченко А.О, Попцов В.Н, Р.Л. Ахмадзай, Гольц А.М., Закирьянов А.Р., Колоскова Н.Н., Захаревич Н.Ю., Никитина Е.А., Поздняков О.А., Кирьяков К.С. Трансплантация сердца как радикальный метод восстановление качества жизни у реципиентов с терминальной стадии сердечной недостаточности. Вестник трансплантологии и искусственных органов. 2019. Т. XXI. № 2. С. 70-73.
  10. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113:1424-33.
  11. Goda A, Williams P, Mancini D, Lund LH. Selecting patients for heart transplantation: comparison of the Heart Failure Survival Score (HFSS) and the Seattle heart failure model (SHFM). J Heart Lung Transplant 2011;30:1236-43.
  12. Levy WC, Mozaffarian D, Linker DT, Farrar DJ, Miller LW. Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy? J Heart Lung Transplant 2009;28:231-6.
  13. Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G, et al. Utility of the Seattle Heart Failure Model in patients with advanced heart failure. J Am Coll Cardiol 2009;53:334-42.
  14. Herz M I. The Registry of the International Society for Heart and Lung Transplantation--Introduction to the 2012 annual reports: new leadership, same vision. J Heart Lung Transplant. 2012;31:1045–1051. 
  15. Arias M, Rush D N, Wiebe C, Gibson I W, Blydt-Hansen T D, Nickerson P W. et al. Antibody-mediated rejection: analyzing the risk, proposing solutions. Transplantation. 2014;98:3–21.[(Suppl 3)].
  16. Mehra M R. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant. 2006; 6:1248–1256. 
  17. Mitchell R N, Libby P. Vascular remodeling in transplant vasculopathy. Circ Res. 2007;100:967–978.
  18. Tuzcu E M, Kapadia S R, Sachar R, Ziada K M, Crowe T D, Feng J. et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol. 2005;45:1538–1542.
  19. Goda A, Williams P, Mancini D, Lund LH. Selecting patients for heart transplantation: comparison of the Heart Failure Survival Score (HFSS) and the Seattle heart failure model (SHFM). J Heart Lung Transplant 2011; 30: 1236-43.
  20. Patel P., Glumova A., LaPorte K., Mahle W.T., Deshpande S.R. High Pulmonary Vascular Resistance in Pediatric Heart Transplant Patients and Role of Sildenafil. The Journal of Heart and Lung Transplantation, Vol. 36, Issue 4, S270.
  21. Ardehali A, Hughes K, Sadeghi A, et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 2001;72:638-41.
  22. Auler Junior JO, Carmona MJ, Bocchi EA, et al. Low doses of inhaled nitric oxide in heart transplant recipients. J Heart Lung Transplant 1996;15:443-50.
  23. De Santo LS, Mastroianni C, Romano G, et al. Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients. Transplant Proc 2008;40:2015-8.
  24. Mikus E, Stepanenko A, Krabatsch T, et al. Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. Eur J Cardiothorac Surg 2011; 40: 971-7.
  25. Kutty RS, Parameshwar J, Lewis C, et al. Use of centrifugal left ventricular assist device as a bridge to candidacy in severe heart failure with secondary pulmonary hypertension. Eur J Cardiothorac Surg 2013; 43:1237-42.
  26. Попцов В.Н., Спирина Е.А., Ухренков С.Г., Алиев Э.З., Хатуцкий В.М., Догонашева А.А. Механическая поддержка кровообращения при ранней дисфункции сердечного трансплантата. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № S. С. 58.
  27. Готье С.В., Попцов В.Н., Захаревич В.М., Шевченко А.О., Спирина Е.А., Ухренков С.Г., Масютин С.А., Алиев Э.З., Воронков В.Ю., Чибисов Н.С., Устин С.Ю., Бондаренко Д.М. Пятилетний опыт применения периферической вено-артериальной экстракорпоральной мембранной оксигенации как метода механической поддержки кровообращения у потенциальных реципиентов сердца.// Вестник трансплантологии и искусственных органов. 2016. Т. 18. № 4. С. 16-25. 
  28. Попцов В.Н., Спирина Е.А., Ухренков С.Г., Бондаренко Д.М., Догонашева А.А., Алиев Э.З. Временная механическая поддержка кровообращения у потенциальных реципиентов сердца. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № 4. С. 113-123.
  29. Готье С.В., Попцов В.Н., Спирина Е.А., Саитгареев Р.Ш., Захаревич В.М., Акопов Г.А., Шумаков Д.В., Закирьянов А.Р., Халилулин Т.А., Гольц А.М., Шевченко А.О., Колоскова Н.Н. Сравнительный анализ факторов, потенциально влияющих на результаты трансплантации сердца, в группах пациентов, ранее оперированных на открытом сердца и ранее не оперированных. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № S. С. 55-56.
  30. Готье С.В., Попцов В.Н., Саитгареев Р.Ш., Шумаков Д.В., Акопов Г.А., Тарабарко Н.Н., Анискевич Г.В. Пересадка сердца после коррекции клапанной патологии сердечного трансплантата.// Вестник трансплантологии и искусственных органов. 2017. Т. 19. № S. С. 65-66.
  31. Попцов В.Н., Спирина Е.А., Масютин С.А., Пчельников В.В., Ухренков С.Г., Алиев Э.З., Устин С.Ю., Хатуцкий В.М., Догонашева А.А. Периоперационный период при трансплантации сердца от доноров 55 лет и старше. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № S. С. 62.
  32. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report — 2007. J Heart Lung Transplant 2007;26:769.
  33. Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplant report — 2009. J Heart Lung Transplant 2009;28:1007.
  34. Leprince P, Aubert S, Bonnet N, et al. Peripheral extracorporeal membrane oxygenation (ECMO) in patients with posttransplant cardiac graft failure. Transplant Proc 2005;37:2879.
  35. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Waltz DA, Keck BM, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-third  official  adult  heart  transplantation report-2006. JHLTX 2006; 25:869-79.
  36. Gardner RS, McDanagh TA, MacDonald M, Dargie HJ, Murday AJ,  Petrie  MC.  Who  needs  a  heart  transplant? Eur  Heart J 2006; 27:770-2.
  37. Hunt SA, Kouretas PC, Balsam LB, Robbins RC. Heart transplantation. In  Zipes  DP,  Libby  P,  Bonow  RO,  Braunwald  E. Braunwald’s Heart Disease. 7 th edition. Elsevier Saunders 2005.
  38. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure.  N Engl J Med 2001; 344 :1651-8.
  39. Lewis EF, Tsang SW, Fang JC, et al. Frequency and impact of delayed decisions regarding heart transplantation on long-term outcomes in patients with advanced heart failure.  J Am Coll Cardiol 2004; 43:794-802.
  40. Feldman D. et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support. The Journal of Heart and Lung Transplantation, 2013 Vol. 32, Issue 2, p157–187.
  41. Иткин Г.П., Попцов В.Н. Механизмы правожелудочковой недостаточности в условиях левожелудочкового вспомогательного кровообращения и методы бивентрикулярного обхода сердца. Вестник трансплантологии и искусственных органов. 2013. Т. X . № 4. С. 126-135.
  42. Kirklin J.K., Naftel D.C., Pagani F.D., et al. Seventh INTERMACS annual report: 15,000 patients and counting. J. Heart Lung Transplant. 2015; 34: 1495– 1504.
  43. Готье С.В., Иткин Г.П., Шемакин С.Ю., Саитгареев Р.Ш, Попцов В.Н., Захаревич В.М., Акопов Г.А., Кормер А.Я., Халилулин Т.А., Шевченко О.П., Невзоров А.М., Филатов И.А., Селищев С.В. Первый опыт клинического применения отечественного аппарата вспомогательного кровообращения на базе имплантируемого осевого насоса для двухэтапной трансплантации сердца. Вестник трансплантологии и искусственных органов. 2013. Т. X . № 3. С. 92-101
  44. Taylor Clare J, Ordóñez-Mena José M, Roalfe Andrea K, Lay-Flurrie Sarah, Jones Nicholas R, Marshall Tom et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study BMJ 2019; 364 :l223
  45. Brown KN, Kanmanthareddy A. Heart Transplantation Patient Selection. [Updated 2020 Oct 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537090/.
  46. Ravichandran AK, Cowger J. Left ventricular assist device patient selection: do risk scores help?. J Thorac Dis. 2015;7(12):2080-2087. doi:10.3978/j.issn.2072-1439.2015.11.02
  47. S. Li, et al.Validity of the Seattle Heart Failure Model after heart failure hospitalization. ESC Heart Fail., 6 (3) (2019), pp. 509-515.
  48. Gorodeski EZ, Chu EC, Chow CH, Levy WC, Hsich E, Starling RC. Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee. Circ Heart Fail 2010;3:706-14.
  49. Pamboukian SV, Tallaj JA, Brown RN, et al. Comparison of observed survival with assist device versus predicted survival without device using the Seattle heart failure model. ASAIO J 2012;58:93-7.
  50. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-7.
  51. Parikh MN, Lund LH, Goda A, Mancini D. Usefulness of peak exercise oxygen consumption and the heart failure survival score to predict survival in patients 465 years of age with heart failure. Am J Cardiol 2009;103:998-1002.
  52. Goda A, Lund LH, Mancini DM. Comparison across races of peak oxygen consumption and heart failure survival score for selection for cardiac transplantation. Am J Cardiol 2010;105:1439-44.
  53. Green P, Lund LH, Mancini D. Comparison of peak exercise oxygen consumption and the Heart Failure Survival Score for predicting prognosis in women versus men. Am J Cardiol 2007;99:399-403.
  54. Lund LH, Aaronson KD, Mancini DM. Validation of peak exercise oxygen consumption and the Heart Failure Survival Score for serial risk stratification in advanced heart failure. Am J Cardiol 2005;95:734-41.
  55. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-86.
  56. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates—2006. J Heart Lung Transplant 2006;25:1024-42.
  57. Stevenson LW, Miller LW, Desvigne-Nickens P, et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation 2004;110:975-81.
  58. Hershberger RE, Nauman D, Walker TL, Dutton D, Burgess D. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail 2003;9:180-7.
  59. Fellahi J.L. et al. Perioperative Use of Dobutamine in Cardiac Surgery and Adverse Cardiac Outcome: Propensity-adjusted Analyses. Anesthesiology. 2008; 108: 979–987.
  60. Rao V, Oz MC, Flannery MA, Catanese KA, Argenziano M, Naka Y. Revised screening scale to predict survival after insertion of a left ventricular assist device. J Thorac Cardiovasc Surg 2003;125:855-62.
  61. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007;116:497-505.
  62. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29.
  63. Schaffer JM, Allen JG, Weiss ES, et al. Evaluation of risk indices in continuous-flow left ventricular assist device patients. Ann Thorac Surg 2009;88:1889-96.
  64. Teuteberg J, Ewald G, Adamson R, et al. Application of the destination therapy risk score to HeartMate II clinical trial data [abstract] [manuscript in press, JACC]. J Heart Lung Transplant 2011;30:S31.
  65. Boyle AJ, Ascheim DD, Russo MJ, et al. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. J Heart Lung Transplant 2011;30:402-7.
  66. Cowger J, Sundareswaran K, Rogers J, et al. The HeartMate II risk score: Predicting survival in candidates for left ventricular assist device support [abstract]. J Heart Lung Transplant 2011;30:S31
  67. S.G. Al Kindi, M. Farhoud, et al. Left ventricular assist devices or inotropes for decreasing pulmonary vascular resistance in patients with pulmonary hypertension listed for heart transplantation J. Card. Fail., 23 (2017), pp. 209-215.
  68. Jennifer Cowger et al. 70 The HeartMate II Risk Score: Predicting Survival in Candidates for Left Ventricular Assist Device Support. April 2011The Journal of Heart and Lung Transplantation 30(4).
  69. Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009;54:312-21.
  70. Goodwin M, Nemeh HW, Borgi J, Paone G, Morgan JA. Resolution of Mitral Regurgitation With Left Ventricular Assist Device Support Ann Thorac Surg. 2017 Sep;104(3):811-818.
  71. Schweiger M1, Stepanenko A, Vierecke J, Drews T, Potapov E, Hetzer R, Krabatsch T. Biological mitral valve prosthesis in a patient supported with a permanent left ventricle assist device. ASAIO J. 2011 Nov-Dec;57(6):550-2.
  72. Choi JH, Luc JGY, Moncho Escrivá E, Phan K, Rizvi SSA, Patel S, Entwistle JW, Morris RJ, Massey HT, Tchantchaleishvili V. Impact of Concomitant Mitral Valve Surgery With LVAD Placement: Systematic Review and Meta-Analysis Artif Organs. 2018 Dec;42(12):1139-1147
  73. Oezpeker C, Zittermann A, Paluszkiewicz L, Piran M, Puehler T, Sayin AO, Ensminger S, Milting H, Morshuis M, Gummert JF. Tricuspid valve repair in patients with left-ventricular assist device implants and tricuspid valve regurgitation: propensity score-adjusted analysis of clinical outcome. Interact Cardiovasc Thorac Surg. 2015 Dec;21(6):741-7
  74. Lahpor JR, de Jonge N, van Swieten HA, Wesenhagen H, Klöpping C, Geertman JH, Oosterom A, Rodermans B, Kirkels JH.Left ventricular assist device as bridge to transplantation in patients with end-stage heart failure: Eight-year experience with the implantable HeartMate LVAS. Neth Heart J. 2002 Jun;10(6):267-271
  75. Morgan JA, Tsiouris A, Nemeh HW, Hodari A, Karam J, Brewer RJ, Paone G. Impact of concomitant cardiac procedures performed during implantation of long-term left ventricular assist devices. J Heart Lung Transplant. 2013 Dec;32(12):1255-61
  76. Kittipibul V, Rattanawong P, Kewcharoen J, Chongsathidkiet P, Vutthikraivit W, Kanjanahattakij N. Atrial Fibrillation Is Not Associated With Thromboembolism in Left Ventricular Assist Device Patients: A Systematic Review and Meta-Analysis. ASAIO J. 2018 Jun 5
  77. Johnsson P, Algotsson L, Ryding E, Stahl E, Messeter K. Cardiopulmonary perfusion and cerebral blood flow in bilateral carotid artery disease. Ann Thorac Surg 1991;51:579-84.
  78. Selim M. Angioplasty and stenting of asymptomatic carotid stenosis before cardiac surgery: more study is needed. Arch Neurol 2008; 65:1672-4.
  79. Lazar HL, Menzoian JO. Coronary artery bypass grafting in patients with cerebrovascular disease. Ann Thorac Surg 1998;66:968-74.
  80. Kato TS, Schulze PC, Yang J, et al. Pre-operative and post-operative risk factors associated with neurologic complications in patients with advanced heart failure supported by a left ventricular assist device. J Heart Lung Transplant 2012;31:1-8.
  81. Wadia Y, Etheridge W, Smart F, Wood RP, Frazier OH. Pathophysiology of hepatic dysfunction and intrahepatic cholestasis in heart failure and after left ventricular assist device support. J Heart Lung Transplant 2005;24:361-70.
  82. Levy JH, Winkler AM. Heparin-induced thrombocytopenia and cardiac surgery. Curr Opin Anaesthesiol 2010;23:74-9.
  83. Morel-Kopp MC, Aboud M, Tan CW, Kulathilake C, Ward C. Whole blood impedance aggregometry detects heparin-induced thrombocytopenia antibodies. Thromb Res 2010;125:e234-9.
  84. Warkentin TE, Greinacher A, Koster A. Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required? Ann Thorac Surg 2009;87:1633-40.
  85. Zucker MJ, Sabnani I, Baran DA, Balasubramanian S, Camacho M. Cardiac transplantation and/or mechanical circulatory support device placement using heparin anti-coagulation in the presence of acute heparin-induced thrombocytopenia. J Heart Lung Transplant 2010;29:53-60.
  86. Butler J, Howser R, Portner PM, Pierson RN 3rd. Diabetes and outcomes after left ventricular assist device placement. J Card Fail 2005;11:510-5.
  87. Topkara VK, Dang NC, Martens TP, et al. Effect of diabetes on short- and long-term outcomes after left ventricular assist device implantation. J Heart Lung Transplant 2005;24:2048-53.
  88. Uriel N, Naka Y, Colombo PC, et al. Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. Eur J Heart Fail 2011;13:195-9.
  89. Kolesar A, Sabol F, Luczy J, Bajmoczi M. Use of left ventricle assist device in a pregnant woman with acute aortic and coronary dissections. Interact Cardiovasc Thorac Surg 2010;11:194-5.
  90. LaRue S, Shanks A, Wang IW, Ewald G, Anderson D, Joseph S. Left ventricular assist device in pregnancy. Obstet Gynecol 2011;118: 426-8.
  91. Oles D, Berryessa R, Campbell K, Bhatti MA. Emergency redo mitral valve replacement in a 27-year-old pregnant female with a clotted prosthetic mitral valve, preoperative fetal demise and postoperative ventricular assist device: a case report. Perfusion 2001;16:159-64. The Journal of Heart and Lung Transplantation, Vol 32, No 2, February 2013 180
  92. Sims DB, Vink J, Uriel N, et al. A successful pregnancy during mechanical circulatory device support. J Heart Lung Transplant 2011;30:1065
  93. Dew MA, DiMartini AF, Steel J, et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. Liver Transpl 2008;14:159-72
  94. Holman WL, Kormos RL, Naftel DC, et al. Predictors of death and transplant in patients with a mechanical circulatory support device: a multi-institutional study. J Heart Lung Transplant 2009;28:44-50.
  95. Adamson RM, Stahovich M, Chillcott S, et al. Clinical strategies and outcomes in advanced heart failure patients older than 70 years of age receiving the HeartMate II left ventricular assist device: a community hospital experience. J Am Coll Cardiol 2011;57:2487-95.
  96. Park SJ, Milano CA, Tatooles AJ, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 2012;5:241-8
  97. Raymond AL, Kfoury AG, Bishop CJ, et al. Obesity and left ventricular assist device driveline exit site infection. ASAIO J 2010;56:57-60.
  98. Zahr F, Genovese E, Mathier M, et al. Obese patients and mechanical circulatory support: weight loss, adverse events, and outcomes. Ann Thorac Surg 2011;92:1420-6.
  99. Brewer RJ, Lanfear DE, Sai-Sudhakar CB, et al. Extremes of body mass index do not impact mid-term survival after continuous-flow left ventricular assist device implantation. J Heart Lung Transplant 2012;31:167-72
  100. Gelow JM, Desai AS, Hochberg CP, Glickman JN, Givertz MM, Fang JC. Clinical predictors of hepatic fibrosis in chronic advanced heart failure. Circ Heart Fail 2010;3:59-64.
  101. Matthews JC, Pagani FD, Haft JW, Koelling TM, Naftel DC, Aaronson KD. Model for end-stage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality. Circulation 2010;121:214-20.
  102. Concha PM, Mertz KV. [Perioperative risk among patients with cirrhosis]. Rev Med Chil 2010;138:1165-71.
  103. Modi A, Vohra HA, Barlow CW. Do patients with liver cirrhosis undergoing cardiac surgery have acceptable outcomes? Interact Cardiovasc Thorac Surg 2010;11:630-4.
  104. Frazier OH, Rose EA, Oz MC, et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 2001; 122:1186-95.
  105. Khan MA, Hussain SF. Pre-operative pulmonary evaluation. J Ayub Med Coll Abbottabad 2005;17:82-6.
  106. Wright DJ, Khan KM, Gossage EM, Saltissi S. Assessment of a low-intensity cardiac rehabilitation programme using the six-minute walk test. Clin Rehabil 2001;15:119-24.
  107. Smetana GW. Preoperative pulmonary evaluation. N Engl J Med 1999;340:937-44.
  108. Smetana GW, Lawrence VA, Cornell JE. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. Ann Intern Med 2006;144:581-95.
  109. Miller LW, Lietz K. Candidate selection for long-term left ventricular assist device therapy for refractory heart failure. J Heart Lung Transplant 2006;25:756-64.
  110. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J 2005;26:153-61.
  111. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-68.
  112. Rady MY, Ryan T. Perioperative predictors of extubation failure and the effect on clinical outcome after cardiac surgery. Crit Care Med 1999;27:340-7.
  113. Samuels LE, Kaufman MS, Morris RJ, Promisloff R, Brockman SK. Coronary artery bypass grafting in patients with COPD. Chest 1998; 113:878-82.
  114. Dimick JB, Chen SL, Taheri PA, Henderson WG, Khuri SF, Campbell DA Jr.. Hospital costs associated with surgical complications: a report from the private-sector National Surgical Quality Improvement Program. J Am Coll Surg 2004;199:531-7.
  115. Bapoje SR, Whitaker JF, Schulz T, Chu ES, Albert RK. Preoperative evaluation of the patient with pulmonary disease. Chest 2007; 132:1637-45.
  116. Arozullah AM, Daley J, Henderson WG, Khuri SF. Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery. The National Veterans Administration Surgical Quality Improvement Program. Ann Surg 2000;232:242-53.
  117. Canet J, Gallart L, Gomar C, et al. Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology 2010;113:1338-50.
  118. Kroenke K, Lawrence VA, Theroux JF, Tuley MR, Hilsenbeck S. Postoperative complications after thoracic and major abdominal surgery in patients with and without obstructive lung disease. Chest 1993;104:1445-51.
  119. Culver BH. How should the lower limit of the normal range be defined? Respir Care 2012;57:136-45.
  120. Sandner SE, Zimpfer D, Zrunek P, et al. Renal function and outcome after continuous flow left ventricular assist device implantation. Ann Thorac Surg 2009;87:1072-8.
  121. Butler J, Geisberg C, Howser R, et al. Relationship between renal function and left ventricular assist device use. Ann Thorac Surg 2006;81:1745-51.
  122. Topkara VK, Dang NC, Barili F, et al. Predictors and outcomes of continuous veno-venous hemodialysis use after implantation of a left ventricular assist device. J Heart Lung Transplant 2006;25:404-8.
  123. Ootaki C, Yamashita M, Ootaki Y, et al. Reduced pulsatility induces periarteritis in kidney: role of the local renin-angiotensin system. J Thorac Cardiovasc Surg 2008;136:150-8.
  124. Radovancevic B, Vrtovec B, de KE, Radovancevic R, Gregoric ID, Frazier OH. End-organ function in patients on long-term circulatory support with continuous- or pulsatile-flow assist devices. J Heart Lung Transplant 2007;26:815-8.
  125. Letsou GV, Myers TJ, Gregoric ID, et al. Continuous axial-flow left ventricular assist device (Jarvik 2000) maintains kidney and liver perfusion for up to 6 months. Ann Thorac Surg 2003;76:1167-70.
  126. Russell SD, Rogers JG, Milano CA, et al. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation 2009;120:2352-7.
  127. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007;357:885-96.
  128. Slaughter MS, Pagani FD, Rogers JG, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 2010;29:S1-39.
  129. Singh M, Shullo M, Kormos RL, et al. Impact of renal function before mechanical circulatory support on posttransplant renal outcomes. Ann Thorac Surg 2011;91:1348-54.
  130. Cupples S, Dew MA, Grady KL, et al. Report of the Psychosocial Outcomes Workgroup of the Nursing and Social Sciences Council of the International Society for Heart and Lung Transplantation: present status of research on psychosocial outcomes in cardiothoracic transplantation: review and recommendations for the field. J Heart Lung Transplant 2006;25:716-25.
  131. Eshelman AK, Mason S, Nemeh H, Williams C. LVAD destination therapy: applying what we know about psychiatric evaluation and management from cardiac failure and transplant. Heart Fail Rev 2009;14:21-8.
  132. Levenson JL, Olbrisch ME. Psychosocial evaluation of organ transplant candidates. A comparative survey of process, criteria, and outcomes in heart, liver, and kidney transplantation. Psychosomatics 1993;34:314-23.
  133. Olbrisch ME, Benedict SM, Ashe K, Levenson JL. Psychological assessment and care of organ transplant patients. J Consult Clin Psychol 2002;70:771-83.
  134. Olbrisch ME, Levenson JL. Psychosocial assessment of organ transplant candidates. Current status of methodological and philosophical issues. Psychosomatics 1995;36:236-43.
  135. De Geest S, Abraham I, Moons P, et al. Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients. J Heart Lung Transplant 1998;17:854-63.
  136. De Geest S, Dobbels F, Martin S, Willems K, Vanhaecke J. Clinical risk associated with appointment noncompliance in heart transplant recipients. Prog Transplant 2000;10:162-8.
  137. De Geest S, Dobbels F, Fluri C, Paris W, Troosters T. Adherence to the therapeutic regimen in heart, lung, and heart-lung transplant recipients. J Cardiovasc Nurs 2005;20:S88-98.
  138. Dew MA, Roth LH, Thompson ME, Kormos RL, Griffith BP. Medical compliance and its predictors in the first year after heart transplantation. J Heart Lung Transplant 1996;15:631-45.
  139. Nagele H, Kalmar P, Rodiger W, Stubbe HM. Smoking after heart transplantation: an underestimated hazard? Eur J Cardiothorac Surg 1997;12:70-4
  140. Pagani FD, Lynch W, Swaniker F, et al. Extracorporeal life support to left ventricular assist device bridge to heart transplant: A strategy to optimize survival and resource utilization. Circulation 1999;100: II206-10.
  141. Aziz TA, Singh G, Popjes E, et al. Initial experience with CentriMag extracorporal membrane oxygenation for support of critically ill patients with refractory cardiogenic shock. J Heart Lung Transplant 2010;29:66-71.
  142. Bagai J, Webb D, Kasasbeh E, et al. Efficacy and safety of percutaneous life support during high-risk percutaneous coronary intervention, refractory cardiogenic shock and in-laboratory cardiopulmonary arrest. J Invasive Cardiol 2011;23:141-7.
  143. Cleveland JC Jr, Naftel DC, Reece TB, et al. Survival after biventricular assist device implantation: an analysis of the Interagency Registry for Mechanically Assisted Circulatory Support database. J Heart Lung Transplant 2011;30:862-9.
  144. Krabatsch T, Schweiger M, Stepanenko A, et al. Mechanical circulatory support-results, developments and trends. J Cardiovasc Transl Res 2011;4:332-9.
  145. Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intraaortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005;26:1276-83.
  146. Engstrom AE, Cocchieri R, Driessen AH, et al. The Impella 2.5 and 5.0 devices for ST-elevation myocardial infarction patients presenting with severe and profound cardiogenic shock: the Academic Medical Center intensive care unit experience. Crit Care Med 2011;39:2072-9.
  147. Koeckert MS, Jorde UP, Naka Y, Moses JW, Takayama H, Impella LP. 2.5 for left ventricular unloading during venoarterial extracorporeal membrane oxygenation support. J Card Surg 2011;26:666-8.
  148. Meyns B, Dens J, Sergeant P, Herijgers P, Daenen W, Flameng W. Initial experiences with the Impella device in patients with cardiogenic shock—Impella support for cardiogenic shock. Thorac Cardiovasc Surg 2003;51:312-7.
  149. Siegenthaler MP, Brehm K, Strecker T, et al. The Impella Recover microaxial left ventricular assist device reduces mortality for postcardiotomy failure: a three-center experience. J Thorac Cardiovasc Surg 2004;127:812-22
  150. Feldman D, Menachemi DM, Abraham WT, Wexler RK. Manage-ment strategies for stage-D patients with acute heart failure. Clin Cardiol 2008;31:297-301.
  151. Farrar DJ. Ventricular interactions during mechanical circulatory support. Semin Thorac Cardiovasc Surg 1994;6:163-8.
  152. Farrar DJ, Compton PG, Hershon JJ, Fonger JD, Hill JD. Right heart interaction with the mechanically assisted left heart. World J Surg 1985;9:89-102.
  153. Dang NC, Topkara VK, Mercando M, et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant 2006;25:1-6.
  154. Kavarana MN, Pessin-Minsley MS, Urtecho J, et al. Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem. Ann Thorac Surg 2002;73:745-50.
  155. Ochiai Y, McCarthy PM, Smedira NG, et al. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation 2002;106:I198-202.
  156. Fitzpatrick JR 3rd, Frederick JR, Hiesinger W, et al. Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg 2009;137:971-7
  157. Tsukui H, Teuteberg JJ, Murali S, et al. Biventricular assist device utilization for patients with morbid congestive heart failure: a justifiable strategy. Circulation 2005;112:I65-72.
  158. Kukucka M, Stepanenko A, Potapov E, et al. Right-to-left ventricular end-diastolic diameter ratio and prediction of right ventricular failure with continuous-flow left ventricular assist devices. J Heart Lung Transplant 2011;30:64-9.
  159. Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol 2008;51:2163-72.
  160. Kirklin JK, Naftel DC, Kormos RL, et al. Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant 2010;29:1-10.
  161. Pagani FD. Continuous-flow rotary left ventricular assist devices with "3rd generation" design. Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):255-63. doi: 10.1053/j.semtcvs.2008.08.002. PMID: 19038736.
  162. Daniel W. Ross, Gerin R. Stevens, Rimda Wanchoo, David T. Majure, Sandeep Jauhar, Harold A. Fernandez, Massini Merzkani, Kenar D. Jhaveri. Left Ventricular Assist Devices and the Kidney. CJASN Feb 2018, 13 (2) 348-355; doi: 10.2215/CJN.04670417.
  163. Tosto, C., Adamo, L., Craddock, H. et al. Relationship between device acceptance and patient-reported outcomes in Left Ventricular Assist Device (LVAD) recipients. Sci Rep 9, 10778 (2019). https://doi.org/10.1038/s41598-019-47324-z.
  164. Furukawa K, Motomura T, Nose Y. Right ventricular failure after left ventricular assist device implantation: the need for an implantable right ventricular assist device. Artif Organs 2005;29:369-77.
  165. Fitzpatrick JR 3rd, Frederick JR, Hsu VM, et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant 2008; 27:1286-92.
  166. Kormos RL, Teuteberg JJ, Pagani FD, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg 2010;139:1316-24
  167. Tedford RJ, Hemnes AR, Russell SD, et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail 2008;1:213-9.
  168. Matamis D, Pampori S, Papathanasiou A, et al. Inhaled NO and sildenafil combination in cardiac surgery patients with out-of-proportion pulmonary hypertension: acute effects on postoperative gas exchange and hemodynamics. Circ Heart Fail 2012;5:47-53.
  169. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001;345:1435-43.
  170. Martin J, Friesewinkel O, Benk C, Sorg S, Schultz S, Beyersdorf F. Improved durability of the HeartMate XVE left ventricular assist device provides safe mechanical support up to 1 year but is associated with high risk of device failure in the second year. J Heart Lung Transplant 2006;25:384-90.
  171. Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2011;57:1890-8.
  172. John R, Kamdar F, Eckman P, et al. Lessons learned from experience with over 100 consecutive HeartMate II left ventricular assist devices. Ann Thorac Surg 2011;92:1593-9.
  173. Cadeiras M, Nagaraj H, Kirklin JK, Holman WL, Pamboukian SV, Misra VK. Use of a vascular plug to percutaneously occlude the outflow conduit of a dysfunctional left ventricular assist device. J Heart Lung Transplant 2011;30:733-4.
  174. Chrysant GS, Horstmanshof DA, Snyder T, et al. Successful percutaneous management of acute left ventricular assist device stoppage. ASAIO J 2010;56:483-5
  175. Holman WL, Skinner JL, Waites KB, Benza RL, McGiffin DC, Kirklin JK. Infection during circulatory support with ventricular assist devices. Ann Thorac Surg 1999;68:711-6.
  176. International Society for Heart and Lung Transplantation. A 2010 working formulation for the standardization of definitions of infections in patients using ventricular assist devices (VADs).
  177. Gordon RJ, Quagliarello B, Lowy FD. Ventricular assist device-related infections. Lancet Infect Dis 2006;6:426-37.
  178. Kimball PM, Flattery M, McDougan F, Kasirajan V. Cellular immunity impaired among patients on left ventricular assist device for 6 months. Ann Thorac Surg 2008;85:1656-61.
  179. Shoham S, Miller LW. Cardiac assist device infections. Curr Infect Dis Rep 2009;11:268-73.
  180. Gristina AG, Dobbins JJ, Giammara B, Lewis JC, DeVries WC. Biomaterial-centered sepsis and the total artificial heart. Microbial adhesion vs tissue integration. JAM 1988;259:870-4.
  181. Padera RF. Infection in ventricular assist devices: the role of biofilm. Cardiovasc Pathol 2006;15:264-70.
  182. Gordon SM, Schmitt SK, Jacobs M, et al. Nosocomial bloodstream infections in patients with implantable left ventricular assist devices. Ann Thorac Surg 2001;72:725-30.
  183. Hanna HA, Raad II, Hackett B, et al. Antibiotic-impregnated catheters associated with significant decrease in nosocomial and multidrugresistant bacteremias in critically ill patients. Chest 2003;124:1030-8.
  184. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1-45.
  185. O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2002;23:759-69.
  186. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999;20:250-78.
  187. Darouiche RO, Wall MJ Jr, Itani KM, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med 2010;362:18-26.
  188. Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR. The Society of Thoracic Surgeons Practice Guideline Series: antibiotic prophylaxis in cardiac surgery, part I: duration. Ann Thorac Surg 2006;81:397-404.
  189. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000;101:2916-21.
  190. Eyler RF, Butler SO, Walker PC, et al. Vancomycin use during left ventricular assist device support. Infect Control Hosp Epidemiol 2009;30:484-6.
  191. Engelman R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice. Ann Thorac Surg 2007;83:1569-76.
  192. Perl TM. Prevention of Staphylococcus aureus infections among surgical patients: beyond traditional perioperative prophylaxis. Surgery 2003;134:S10-7.
  193. Holman WL, Park SJ, Long JW, et al. Infection in permanent circulatory support: experience from the REMATCH trial. J Heart Lung Transplant 2004;23:1359-65.
  194. Myers TJ, Khan T, Frazier OH. Infectious complications associated with ventricular assist systems. ASAIO J 2000;46:S28-36.
  195. Pasque MK, Hanselman T, Shelton K, et al. Surgical management of Novacor drive-line exit site infections. Ann Thorac Surg 2002;74:1267-8.
  196. Zierer A, Melby SJ, Voeller RK, et al. Late-onset driveline infections: the Achilles’ heel of prolonged left ventricular assist device support.Ann Thorac Surg 2007;84:515-20.
  197. Chinn R, Dembitsky W, Eaton L, et al. Multicenter experience: prevention and management of left ventricular assist device infections. ASAIO J 2005;51:461-70.
  198. Garatti A, Giuseppe B, Russo CF, Marco O, Ettore V. Drive-line exitsite infection in a patient with axial-flow pump support: successful management using vacuum-assisted therapy. J Heart Lung Transplant 2007;26:956-9.
  199. Hravnak M, George E, Kormos RL. Management of chronic left ventricular assist device percutaneous lead insertion sites. J Heart Lung Transplant 1993;12:856-63.
  200. Makdisi G, Jan MY, Dungy-Poythress L, Wang IW, Caccamo MA. Successful Delivery in a Patient With Left Ventricular Assist Device and Unplanned Pregnancy. Ann Thorac Surg. 2017 Jul;104(1):e31-e33. doi: 10.1016/j.athoracsur.2017.01.071. PMID: 28633256.
  201. Westcott JM, Yaghoubian Y, Williams MR, Roman AS, Hughes F, Rosner M. Prophylactic percutaneous left ventricular assist device in pregnancy. Obstetric Medicine. 2019;12(3):151-152.
  202. Desai, N, Chaudhry, K, Aji, J. Impella left ventricular assist device in cardiac arrest after spinal anaesthesia for caesarean section. BMJ Case Rep 2015. DOI: 10.1136/bcr-2015-211958.
  203. Seyed Hamed Hosseini Dehkordi et al. Successful pregnancy and delivery with centrifugal flow left ventricular assist device. J Am Coll Cardiol. 2020 Mar, 75.
  204. A.K. Johnson et al. Substance Abuse and Left Ventricular Assist Device Outcomes: Does a History and Type of Use Matter?. The Journal of Heart and Lung Transplantation. Abstract. Volume 34, Issue 4, Supplement , S191-192, april 01, 2015.
  205. Holmes EC. Outpatient management of long-term assist devices. Cardiol Clin 2003;21:93-9.
  206. Wilson SR, Givertz MM, Stewart GC, Mudge GH Jr. Ventricular assist devices: the challenges of outpatient management. J Am Coll Cardiol 2009;54:1647-59.
  207. Morgan JA, Edwards NM. Orthotopic cardiac transplantation: comparison of outcome using biatrial, bicaval, and total techniques. J Card Surg. 2005;20: 102-106.
  208. Трансплантация сердца. Руководство для врачей /Под ред. С.В. Готье, В.Н. Попцова, А.О. Шевченко. – М. – Тверь: ООО «Издательство «Триада». – 2014.
  209. Chen EP, Bittner HB, Davis RD, Van TP. Hemodynamic and inotropic effects of milrinone after heart transplantation in the setting of recipient pulmonary hypertension. J Heart Lung Transplant 1998;17: 669-78.
  210. Leyh RG, Kofidis T, Struber M, et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg 2003;125:1426-31.
  211. Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96(9 suppl):II-90.
  212. Morales DL, Garrido MJ, Madigan JD, et al. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardio- pulmonary bypass. Ann Thorac Surg 2003;75:926-30.
  213. Armitage JM, Hardesty RL, Griffith BP. Prostaglandin E1: an effective treatment of right heart failure after orthotopic heart transplantation. J Heart Transplant 1987;6:348-51.
  214. Pascual JM, Fiorelli AI, Bellotti GM, Stolf NA, Jatene AD. Prostacyclin in the management of pulmonary hypertension after heart transplantation. J Heart Transplant 1990;9:644-51.
  215. Theodoraki K, Tsiapras D, Tsourelis L, et al. Inhaled iloprost in eight heart transplant recipients presenting with post-bypass acute right ventricular dysfunction. Acta Anaesthesiol Scand 2006;50:1213-7.
  216. J. Patel,M. Kittleson,L. Czer,T. Aintablian,R. Sharoff,G. Rodriguez,B. Kearney,N. Perry,A. Hage,F. Esmailian,J.A. Kobashigawa. Severity of Hypertension After Heart Transplant: Does It Impact Outcome?. The Journal of Heart and Lung Transplantation. April 2016. doi:10.1016/j.healun.2016.01.840.
  217. Tanveer A.KhanMD et. al. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. The Journal of Thoracic and Cardiovascular Surgery. Volume 138, Issue 6, December 2009, Pages 1417-1424. doi:10.1016/j.jtcvs.2009.04.063.
  218. R. K. Singh et al. The Use of Oral Sildenafil for Management of Right Ventricular Dysfunction After Pediatric Heart Transplantation. American Journal of Transplantation 2014; 14: 453–458.
  219. Kirklin JK, Young JB, McGiffin DC. Heart transplantation. Philadelphia: Churchill Livingstone, 2002.
  220. Bauer J, Dapper F, Demirakca S, et al. Perioperative management of pulmonary hypertension after heart transplantation in childhood. J Heart Lung Transplant 1997;16:1238-47
  221. Addonizio LJ, Gersony WM, Robbins RC, et al. Elevated pulmonary vascular resistance and cardiac transplantation. Circulation 1987;76: V52-5.
  222. Gao SZ, Hunt SA, Wiederhold V, Schroeder JS. Characteristics of serial electrocardiograms in heart transplant recipients. Am Heart J 1991;122:771-4.
  223. Holt ND, McComb JM. Cardiac transplantation and pacemakers: when and what to implant. Card Electrophysiol Rev 2002;6:140-51.
  224. Vaseghi M, Boyle NG, Kedia R, et al. Supraventricular tachycardia after orthotopic cardiac transplantation. J Am Coll Cardiol 2008;51: 2241-9.
  225. Kemkes BM, Schutz A, Engelhardt M, Brandl U, Breuer M. Noninvasive methods of rejection diagnosis after heart transplantation. J HeartLungTransplant 1992;11:S221-31.
  226. Keteyian S, Shepard R, Ehrman J, et al. Cardiovascular responses of heart transplant patients to exercise training. J ApplPhysiol 1991;70: 2627-31.
  227. Kobashigawa JA, Leaf DA, Lee N, et al. A controlled trial of exercise rehabilitation after heart transplantation. N Engl J Med 1999;340: 272-7.
  228. Kavanagh T, Yacoub MH, Kennedy J, Austin PC. Return to work after heart transplantation: 12-year follow-up. J HeartLungTransplant1999;18:846-51.
  229. Paris W, Woodbury A, Thompson S, et al. Social rehabilitation and return to work after cardiac transplantation—a multicenter survey. Transplantation 1992;53:433-8.
  230. McCartney S.L., Patel C., Del Rio J.M.  Long-term outcomes and management of the heart transplant recipient. Best Pract Res Clin Anaesthesiol. 2017;31(2):237-248. doi: 10.1016/j.bpa.2017.06.003. 
  231. Lindenfeld J, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel EE, Mestroni L, Page RL 2nd, Kobashigawa J. Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. Circulation. 2004 Dec 14;110(24):3734-40. doi: 10.1161/01.CIR.0000149745.83186.89.
  232. Tsunoda SM, Aweeka FT. Drug concentration monitoring of immunosuppressive agents: focus on tacrolimus, mycophenolate mofetil and sirolimus. BioDrugs2000;14:355-69.
  233. Hyunyoung Jeong, Bruce Kaplan. Therapeutic Monitoring of Mycophenolate Mofetil. CJASN Jan 2007, 2 (1) 184-191; DOI: 10.2215/CJN.02860806.
  234. Kaczmarek I. et al. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results. The Journal of Heart and Lung Transplantation. Volume 32, issue 3, p277-284, march 01, 2013.
  235. Baran DA, Zucker MJ, Arroyo LH, et al. Randomized trial of tacrolimus monotherapy: tacrolimus in combination, tacrolimus alone compared (the TICTAC trial). J Heart Lung Transplant 2007;26:992-7.
  236. Murphy J, Frantz R, Cooper L. Endomyocardial biopsy. In: Murphy J, Lloyd M, editors. Mayo Clinic Cardiology Concise Textbook. Minnesota: Rochester; 2007. p. 1481.
  237. Strecker T et al.  Endomyocardial biopsy for monitoring heart transplant patients: 11-years-experience at a german heart center. Int J Clin Exp Pathol. 2013; 6(1): 55–65
  238. Murray H. Kwon, Richard J. Shemin; Tricuspid valve regurgitation after heart transplantation; Ann Cardiothorac Surg. 2017 May; 6(3): 270–274.
  239. Briasoulis A, Inampudi C, Pala M, Asleh R, Alvarez P, Bhama J.Induction immunosuppressive therapy in cardiac transplantation: a systematic review and meta-analysis. Heart Fail Rev. 2018 Sep;23(5):641-649. doi: 10.1007/s10741-018-9691-2.
  240. Daniel Marelli, MD, Fardad Esmailian, MD, Fardad Esmailian ,MD, Samantha Y. Wong, BS, Jon A. Kobashigawa, MD, Murray H. Kwon, MD, Ramin E. Beygui, MD, Hillel Laks, MD, Mark D. Plunkett, MD, Abbas Ardehali, MD, Richard J. Shemin, MD; Tricuspid valve regurgitation after heart transplantation; The Journal of Thoracic and Cardiovascular Surgery; June 2009 Volume 137, Issue 6, Pages 1557–1559.
  241. Koloskova N.N., Poptsov V.N., Shevchenko A.O. The individual tailoring of immunosuppressive therapy after heart transplantation. Vestnik transplantologii i iskusstvennyh organov 2018;(926):127-137. DOI: 10.15825/1995-1191-2018-1-127-137.
  242. Zuckermann A, Schulz U, Deuse T, Ruhpawar A et al. Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression. Transpl. Int. 2015 Mar; 28 (3): 259–269.
  243. Schweiger М. Immunosuppressive Therapy After Cardiac Transplantation. Medical University Graz, Department for Surgery, Division for Transplantation Surgery, Austria. 4–5.
  244. Lars H Lund, Leah B Edwards, Anna Y Kucheryavaya et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report–2015; Focus Theme: Early Graft Failure. The Journal of Heart and Lung Transplantation. 2015; 34 (10): 1245–1253.
  245. Taylor DO, Bristow MR, O’Connell JB, Price GD, Hammond EH, Doty DB, Karwande SV, Gay WA Jr, Jones KW, Lappe D, Renlund DG. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. J Heart Lung Transplant. 1996; 15: 1039–1046.
  246. Kobashigawa JA, Stevenson LW, Brownfield ED, Gleeson MP, Moriguchi JD, Kawata N, Minkley R, Drinkwater DC, Laks H. Corticosteroid weaning late after heart transplantation: relation to HLA-DR mismatching and long-term metabolic benefits. J Heart Lung Transplant. 1995; 14: 963–967
  247. Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large European trial. Am J Transplant 2006; 6:1387. 
  248. Groetzner J, Meiser BM, Schirmer J, et al. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up? Transplant Proc 2001; 33:1461.
  249. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation 2004;110:3858-65.
  250. Meiser BM, Uberfuhr P, Fuchs A, et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant 1998; 17:782. 
  251. Rinaldi M, Pellegrini C, Martinelli L, et al. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. J Heart Lung Transplant 1997; 16:1001. 
  252. Reichart B, Meiser B, Vigano M., et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results--European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant 1998; 17:775. 
  253. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18:336.
  254. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377-86.
  255. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-58.
  256. Halloran PF, Gourishankar S. Principles and overview of immunosuppression. In: Norman DJ, Laurel NJ, editors. Primer on transplantation. Mt Laurel, NJ: American Society of Transplantation; 2001. p. 87-98.
  257. Baran DA, Zucker MJ, Arroyo LH, et al. Randomized trial of tacrolimus monotherapy: tacrolimus in combination, tacrolimus alone com- pared (the TICTAC trial). J Heart Lung Transplant 2007;26:992-7.
  258. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004;110:2694-700.
  259. Lehmkuhl H, Livi U, Arizon J, et al. Results of a 12-month, multicenter, randomized trial of everolimus with reduced-exposure cyclosporine versus mycophenolate mofetil and standard exposure cyclosporine in de novo cardiac transplantation recipients. J Heart Lung Transplant 2008;27(2S):S65.
  260. Raichlin E, Khalpey Z, Kremers W, et al. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation 2007; 84: 467-74.
  261. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004; 77: 568-74.
  262. Stenton SB, Partovi N, Ensom MH. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet 2005; 44: 769-86.
  263. Brandhorst G, Tenderich G, Zittermann A, et al. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Ther Drug Monit 2008;30:113-6.
  264. Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol 1990; 1: 162-79.
  265. Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant 2005; 24: 63- 6.
  266. Mehra MR, Uber PA, Vivekananthan K, et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 2002; 40:1609-14.
  267. Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005; 24:1736-40.
  268. Chin C, Lukito SS, Shek J, Bernstein D, Perry SB. Prevention of pediatric graft coronary artery disease: atorvastatin. Pediatr Transplant 2008;12:442-6.
  269. Муминов И.И., Шевченко А.О. Клиническая эффективность и безопасность ингибиторов ГМГ-КоА-редуктазы у реципиентов трансплантированного сердца Трансплантология: итоги и перспективы. Том VIII. 2016 год    Под ред. С.В. Готье. – М. – Тверь: ООО «Издательство «Триада», 2017. – 368 с.
  270. Шевченко А.О., Халилулин Т.А., Шевченко О.П. Механизмы нелипидного действия статинов у реципиентов сердца. Вестн. транспл. и искусств. орг. 2013; 2: 142–147.
  271. Gazi I., Liberopoulos E., Athyros V. et al. Statins and solid organ transplantation // Curr. Pharm. Des. – 2006; 12: 4771–83.
  272. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 2004;75:101-9.
  273. Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant 2005;24:63-6.
  274. Chin C, Lukito SS, Shek J, Bernstein D, Perry SB. Prevention of pediatric graft coronary artery disease: atorvastatin. Pediatr Transplant 2008;12:442-6.
  275. Heublein B, Wahlers T, Haverich A. Pulsed steroids for treatment of cardiac rejection after transplantation. What dosage is necessary? Circulation1989;80:III97-9.
  276. Lonquist JL, Radovancevic B, Vega JD, et al. Reevaluation of steroid tapering after steroid pulse therapy for heart rejection. J Heart Lung Transplant 1992;11:913-9.
  277. Haverty TP, Sanders M, Sheahan M. OKT3 treatment of cardiac allograft rejection. J Heart Lung Transplant 1993;12:591-8.
  278. Crow S. et al. Efficacy and Safety of Anti-thymocyte Globulin for the Treatment of Acute Cellular Rejection in Orthotopic Heart Transplant. Journal of Cardiac Failure. 2015; 21 (8): S117-S118
  279. Onsager DR, Canver CC, Jahania MS, et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant 1999;18:448-55.
  280. Chan MC, Kwok BW, Shiba N, et al. Conversion of cyclosporine to tacrolimus for refractory or persistent myocardial rejection. Transplant Proc 2002;34:1850-2.
  281. Hutter JA, Wallwork J, English TA. Management of rejection in heart transplant recipients: does moderate rejection always require treatment? J Heart Transplant. 1990;9(2):87-91
  282. Carrier  M.  Noninvasive assessment of cardiac transplant rejection. A critical look at the approach to acute rejection. 1991 Dec;34(6):569-72
  283. Keogh AM, Arnold RH, Macdonald PS, et al. A randomized trial of tacrolimus (FK506) versus total lymphoid irradiation for the control of repetitive rejection after cardiac transplantation. J Heart Lung Transplant 2001;20:1331-4.
  284. Ibrahim M, Hendry P, Masters R, et al. Management of acute severe perioperative failure of cardiac allografts: a single-centre experience with a review of the literature. Can J Cardiol 2007;23:363-7.
  285. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004;4:1033-41.
  286. Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant 2001;20:316-21.
  287. Kaczmarek I, Deutsch MA, Sadoni S, et al. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. J Heart Lung Transplant 2007;26:511-5.
  288. Garrett HE Jr, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant 2005;24:1337-42.
  289. Rose ML, Smith J, Dureau G, Keogh A, Kobashigowa J. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 2002;21:282-5.
  290. Itescu S, Burke E, Lietz K, et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 2002;105:1214-9.
  291. Leech SH, Lopez-Cepero M, LeFor WM, et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transplant 2006;20:476-84.
  292. Kfoury AG, Hammond ME, Snow GL, et al. Early screening for antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 2007;26:1264-9.
  293. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003;22:58-69.
  294. Miller LW, Wesp A, Jennison SH, et al. Vascular rejection in heart transplant recipients. J Heart Lung Transplant 1993;12:S147-52.
  295. Brunner-La Rocca HP, Schneider J, Kunzli A, Turina M, Kiowski W. Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease. Transplantation 1998;65:538-43.
  296. Klingenberg R, Koch A, Schnabel PA, et al. Allograft rejection of ISHLT grade #/#3A occurring late after heart transplantation—a distinct entity? J Heart Lung Transplant 2003;22:1005-13.
  297. The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiologie. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005; 26:1115-40
  298. Krum H, Roecker EB, Mohacsi P, et al. Effects of Initiating Carvedilol in Patients With Severe Chronic Heart Failure: Results From the COPERNICUS Study. JAMA. 2003;289(6):712–718. doi:10.1001/jama.289.6.712.
  299. Amedeo Chiribiri, MD et al. Long-term Follow-up of Patients Eligible, Deferred, or Ineligible for Heart Transplantation. Clinical heart transplantation; volume 27, issue 4, p380-386, april 01, 2008. doi: 10.1016/j.healun.2008.01.011.
  300. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108:48-53.
  301. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation. 1999 Nov 27;68(10):1526-32. doi: 10.1097/00007890-199911270-00016.
  302. Sheila A Doggrell. Is everolimus useful in preventing allograft rejection and vasculopathy after heart transplant?. J. Expert opinion on investigational drugs. Volume 13, 2004 - Issue 2.
  303. Kobashigawa JA, Tobis JM, Mentzer RM, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant 2006;6:993-7.
  304. Kapadia SR, Nissen SE, Ziada KM, et al. Development of transplantation vasculopathy and progression of donor-transmitted atheroscle rosis: comparison by serial intravascular ultrasound imaging. Circulation 1998;98:2672-8.
  305. Johl M et al. Use of the Annual Angiogram After Heart Transplantation: Are They All Necessary? Circulation. 2017;136:A18380
  306. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 2005;45:1532-7.
  307. Nicolas RT, Kort HW, Balzer DT, et al. Surveillance for transplant coronary artery disease in infant, child and adolescent heart transplant recipients: an intravascular ultrasound study. J Heart Lung Transplant 2006;25:921-7.
  308. Kuhn MA, Jutzy KR, Deming DD, et al. The medium-term findings in coronary arteries by intravascular ultrasound in infants and children after heart transplantation. J Am Coll Cardiol 2000;36:250-4.
  309. Farzaneh-Far A. Electron-beam computed tomography in the assessment of coronary artery disease after heart transplantation. Circulation 2001;103:E60.
  310. Pichler P, Loewe C, Roedler S, et al. Detection of high-grade stenoses with multislice computed tomography in heart transplant patients.J Heart Lung Transplant 2008;27:310-6.
  311. Elkaryoni A et al  Diagnostic accuracy of dobutamine stress echocardiography in the detection of cardiac allograft vasculopathy in heart transplant recipients: A systematic review and meta-analysis study. Echocardiography. 2019;36(3):528-536. doi: 10.1111/echo.14268.  
  312. Hacker M, Hoyer HX, Uebleis C, et al. Quantitative assessment of cardiac allograft vasculopathy by real-time myocardial contrast echo-cardiography: a comparison with conventional echocardiographic analyses and [Tc99m]-sestamibi SPECT. Eur J Echocardiogr 2008; 9:494-500.
  313. Sakamoto T, Yamada T. Hemodynamic effects of dobutamine in patients following open heart surgery. Circulation. 1977. 1977;55:525–533
  314. Mehra MR. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 2006;6:1248-56.
  315. Botha P, Peaston R, White K, et al. Smoking after cardiac transplantation. Am J Transplant 2008;8:866-71.
  316. McDonald K, Rector TS, Braulin EA, Kubo SH, Olivari MT. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol 1989;64:359-62.
  317. Simmonds J, Fenton M, Dewar C, et al. Endothelial dysfunction and cytomegalovirus replication in pediatric heart transplantation. Circulation 2008;117:2657-61.
  318. Hussain T, Burch M, Fenton MJ, et al. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation 2007;115:1798-1805.
  319. Kato T, Chan MC, Gao SZ, et al. Glucose intolerance, as reflected by hemoglobin A1c level, is associated with the incidence and severity of transplant coronary artery disease. J Am Coll Cardiol 2004;43:1034-41.954
  320. Schroeder JS, Gao SZ, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 1993;328:164-70.
  321. Erinc K, Yamani MH, Starling RC, et al. The effect of combined Angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultra-sound. J Heart Lung Transplant 2005;24:1033-8.
  322. Halle AA, III, DiSciascio G, Massin EK, et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 1995;26:120-8.
  323. Aqel RA, Wells BJ, Hage FG, et al. Re-stenosis after drug-eluting stents in cardiac allograft vasculopathy. J Heart Lung Transplant 2008;27:610-5.
  324. Radovancevic B, McGiffin DC, Kobashigawa JA, et al. Retransplantation in 7,290 primary transplant patients: a 10-year multi-institutional study. J Heart Lung Transplant 2003;22:862-8.
  325. Farzaneh-Far A. Electron-beam computed tomography in the assessment of coronary artery disease after heart transplantation. Circulation 2001; 103: E60.
  326. Cardiac retransplantation is an efficacious therapy for primary cardiac allograft failure / P. Atluri, W. Hiesinger, R.C. Gorman et al. // J. Cardiothoracic Surg. – 2008. – 7. – P. 3-26. doi: 10.1186/1749-8090-3-26.
  327. Retransplantation in 7290 primary transplant patients: a 10-year multi-institutional study / B. Radovancevic, D.C. McGiffin, J.A. Kobashigawa, et al. // J. Heart Lung Transplant. – 2003. – 22. – P.862-8.
  328. Ross retransplant and medical therapy for cardiac allograft vasculopathy: International Society for Heart and Lung Transplantation registry analysis /L.A. Goldraich, J. Stehlik, A.Y. Kucheryavaya, L.B. Edwardsand // American Journal of Transplantation. – 2016. – 16. – P. 301-309.
  329. Heart retransplantation / M.R. Johnson, K.D. Aaronson, C.E. Canter et al. //Am J Transplant. – 2007. – 7. – P.2075-81.
  330. Андрющенко А.В., Арутюнов Г.П., Атьков О.Ю., Балахонова Т.В., Баранова Е.И., Большакова О.О., Васичкина Е.С., Васюк Ю.А., Галявич А.С., Гордеев М.Л., Готье С.В., Гудкова А.Я., Гурщенков А.В., Демин А.А., Демченко Е.А., Дземешкевич С.Л., Звартау Н.Э., Земцовский Э.В., Золотухин И.А., Карпов Р.С., Шевченко А.О. и др. КАРДИОЛОГИЯ. НАЦИОНАЛЬНОЕ РУКОВОДСТВО. Краткое издание / Москва, 2018. (2-е издание, переработанное и дополненное).
  331. Шевченко А.О., Никитина Е.А., Тюняева И.Ю. Артериальная гипертония у реципиентов трансплантированного сердца. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № 2. С. 114-125.
  332. Ambrosi P, Kreitmann B, Habib G. Does heart rate pre- dict allograft vasculopathy in heart transplant recipients? Int. J. Cardiol. 2010; 145: 256–257.
  333. Lehoux S, Tedgui A. Signal transduction of mechanical stresses in the vascular wall. Hypertension. 1998; 32: 338–345.
  334. Васюк ЮА,  Иванова  СВ,  Школьник  ЕЛ,  Котовская ЮВ, Милягин ВА, Олейников ВЭ, Орлова ЯА и др. Согласованное мнение российских  экспертов  по оценке артериальной жесткости в клинической практике. Кардиоваскулярная терапия и профилактика. 2016; 15 (2): 4–19. Vasyuk YuA, Ivanova SV, Shkol’nik EL, Kotovskaya YuV, Milyagin VA, Oleynikov VE, Orlova YaA i dr. Soglasovannoe mnenie rossiyskikh ekspertov po otsenke arterial’noy zhestkosti v klinicheskoy praktike. Kardiovaskulyarnaya terapiya i profilaktika. 2016; 15 (2): 4–19.
  335. Shevchenko AO, Tunyaeva IU, Nasyrova AA. Common carotid artery wall rigidity index is a mаrker of cardiac allograft rejection. The Journal of Heart and Lung Transplantation. 2015; 4S: S298.
  336. Nichols WW, Denardo SJ, Wilkinson IB, McEniery CM, Cockcroft J, O’Rourke MF. Effects of arterial stiffness, pulse wave velocity, and wave reflections on the central aortic pressure waveform. J. Clin. Hypertens. (Greenwich). 2008; 10 (4): 295–303.
  337. Насырова АА, Шевченко АО. Функциональные показатели магистральных артерий и риск отторжения трансплантированного сердца. Трансплантация: итоги и перспективы. Том VII. 2015 год. Под ред. С.В. Готье. М.–Тверь: Триада, 2016: 331–350. Nasyrova AA, Shevchenko AO. Funktsional’nye pokazateli magistral’nykh arteriy i risk ottorzheniya transplantiro- vannogo serdtsa. Transplantatsiya: itogi i perspektivy. Tom VII. 2015 god. Pod red. S.V. Gautier. M.–Tver’: Triada, 2016: 331–350.
  338. Бойцов СА. Изучение патогенеза гипертонической болезни продолжается. Терапевтический архив. 2006; 78 (9): 1–12. Boytsov SA. Izuchenie patogeneza gipertonicheskoy bolezni prodolzhaetsya. Terapevticheskiy arkhiv. 2006; 78 (9): 1–12.
  339. Braith RW, Mills RM, Wilcox CS et al. Breakdown of blood pressure and body fluid homeostasis in heart trans- plant recipients. J. Am. Coll. Cardiol. 1996; 27: 375–383.
  340. Braith RW, Mills RM, Wilcox CS et al. Fluid homeostasis after heart transplantation: the role of cardiac denervation. J. Heart Lung Transplant. 1996; 15: 872–880.
  341. Braith RW, Mills RM, Wilcox CS et al. High dose angiotensin-converting enzyme inhibition prevents fluid volume expansion in heart transplant recipients. Journal of the American College of Cardiology. 2000; 36 (2): 487–492.
  342. Zimmer RJ, Lee MS. Transplant Coronary Artery Disease. JACC: Cardiovascular Interventions. 2010; 3 (4): 367–377.
  343. Borgese L, Potena L, Resciniti E et al. Influence of angiotensin-type1-receptor antibodies in chronic vascular injury on heart transplant patients. The Journal of Heart and Lung Transplantation. 2015; 34 (4): 99–S100.
  344. Canzanello VJ, Textar SC, Taler SJ et al: Late hypertension after liver transplantation: A comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl Surg, 1998; 4: 328–34.
  345. Можейко Н.П., Ильинский И.М., Миронков Б.Л., Попцов В.Н., Колоскова Н.Н., Шевченко А.О., Шевченко О.П. Острое клеточное отторжение в поздние сроки после трансплантации сердца. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № S. С. 77.
  346. Шевченко А.О., Тюняева И.Ю., Насырова А.А., Миронков Б.Л., Ильинский И.М., Можейко Н.П., Муминов И.И., Шевченко О.П. Отторжение сердечного трансплантата и неинвазивные показатели функционального состояния стенки общей сонной артерии. Вестник трансплантологии и искусственных органов. 2015. Т. 17. № 1. С. 5-11.
  347. Саховский С.А., Изотов Д.А., Колоскова Н.Н., Муминов И.И., Ахмадзай Р.Л., Фараджов Р.А., Спирина Е.А., Попцов В.Н., Миронков Б.Л., Шевченко А.О. Ангиографическая оценка атеросклеротического поражения коронарных артерий сердечного трансплантата. Вестник трансплантологии и искусственных органов. 2018. Т. 20. № 4. С. 22-29.
  348. Попцов В.Н., Спирина Е.А., Ухренков С.Г., Мебония Н.З., Пчельников В.В., Масютин С.А., Воронков В.Ю., Алиев Э.З. Анестезия и интенсивная терапия при трансплантации сердца у возрастных реципиентов. Вестник трансплантологии и искусственных органов. 2016. Т. 18. № S. С. 29.
  349. Шевченко А.О., Готье С.В., Попцов В.Н., Саитгареев Р.Ш., Захаревич В.М., Шумаков Д.В. Тридцатилетняя динамика показателей выживаемости больных терминальной сердечной недостаточностью после трансплантации сердца по данным регистра ФНЦТИО им. ак. В.И. ШУМАКОВА. Евразийский кардиологический журнал. 2016. № 3. С. 171-172.
  350. Готье С.В., Попцов В.Н., Саитгареев Р.Ш., Шумаков Д.В., Захаревич В.М., Спирина Е.А. Научно-технологические и организационные решения по повышению эффективности и своевременности выполнения трансплантации сердца. Вестник трансплантологии и искусственных органов. 2014. Т. 16. № 3. С. 14-22.
  351. Габриэлян Н.И., Савостьянова О.А., Горская Е.М., Батыршина Л.Р., Ромашкина Л.Ю., Попцов В.Н., Акимкин В.Г. Эпидемиологическая и микробиологическая характеристика послеоперационного периода у пациентов старшего возраста в кардиохирургии. Эпидемиология и вакцинопрофилактика. 2015. Т. 14. № 5 (84). С. 51-55.
  352. Романова Н.И., Горская Е.М., Есенова Н.М., Захаревич В.М., Саитгареев Р.Ш., Габриэлян Н.И. Микрофлора внешней среды как угроза развития инфекционной патологии у пациентов после ортотопической трансплантации сердца. Медицинский алфавит. 2016. Т. 1. № 6 (269). С. 47-55.
  353. Blasco LM, Parameshwar J, Vuylsteke A. Anaesthesia for noncardiac surgery in the heart transplant recipient. Curr Opin Anaesthesiol 2009;22:109-13.
  354. Dobbels F, Van Damme-Lombaert R, Vanhaecke J, De GS. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant 2005;9:381-90.
  355. Aqel RA, Wells BJ, Hage FG, et al. Restenosis after drug-eluting stents in cardiac allograft vasculopathy. J Heart Lung Trans- plant 2008;27:610-5.
  356. Миронков Б.Л. Эндоваскулярные вмешательства у пациентов с трансплантированным сердцем. Вестник трансплантологии и искусственных органов. 2015. Т. 17. № 2. С. 77-79.
  357. Миронков Б.Л., Честухин В.В., Тюняева И.Ю., Рядовой И.Г., Остроумов Е.Н., Шевченко А.О., Миронков А.Б., Кормер А.Я. Клиническая эффективность реваскуляризации миокарда при васкулопатии сердечного трансплантата. Вестник трансплантологии и искусственных органов. 2014. Т. 16. № 4. С. 5-10.
  358. Halle AA, III, DiSciascio G, Massin EK, et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 1995; 26:120-8.
  359. Готье С.В., Попцов В.Н., Саитгареев Р.Ш., Шумаков Д.В., Захаревич В.М., Халилулин Т.А., Гольц А.М., Акопов Г.А., Закирьянов А.Р., Миронков Б.Л., Шевченко А.О., Можейко Н.П. Стратегия ретрансплантации сердца: результаты и проблемы. Вестник трансплантологии и искусственных органов. 2016. Т. 18. № S. С. 32. 
  360. Готье С.В., Попцов В.Н., Саитгареев Р.Ш., Захаревич В.М., Шевченко А.О., Акопов Г.А., Халилулин Т.А., Гольц А.М., Закирьянов А.Р., Колоскова Н.Н. Ретрансплантация сердца - единственный эффективный метод лечения терминальной дисфункции сердечного трансплантата. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № S. С. 63-64.
  361. Paris W, Woodbury A, Thompson S, et al. Social rehabilitation and return to work after cardiac transplantation-a multicenter survey. Transplantation 1992;53: 433-8.
  362. Саитгареев Р.Ш., Захаревич В.М., Гольц А.М., Халилулин Т.А., Борисов Д.В. Ретрансплантация сердца. Вестник трансплантологии и искусственных органов. 2016. Т. 18. № 2. С. 142-151.
  363. Keteyian S, Shepard R, Ehrman J, et al. Cardiovascular responses of heart transplant patients to exercise training. J Appl Physiol 1991;70: 2627-31.
  364. Kobashigawa JA, Leaf DA, Lee N, et al. A controlled trial of exercise rehabilitation after heart transplantation. N Engl J Med 1999; 340 : 272-7. 
  365. Braith RW, Schofield RS, Hill JA, Casey DP, Pierce GL. Exercise training attenuates progressive decline in brachial artery reactivity in heart transplant recipients. J Heart Lung Transplant 2008;27:52-9. 
  366. Pierce GL, Schofield RS, Casey DP, et al. Effects of exercise training on forearm and calf vasodilation and proinflammatory markers in recent heart transplant recipients: a pilot study. Eur J Cardiovasc Prev Rehabil 2008;15:10-8.
  367. Haykowsky M, Taylor D, Kim D, Tymchak W. Exercise training improves aerobic capacity and skeletal muscle function in heart transplant recipients. Am J Transplant 2009;9:734-9.
  368. Braith RW, Magyari PM, Fulton MN, et al. Resistance exercise training and alendronate reverse glucocorticoid-induced osteoporosis in heart transplant recipients. J Heart Lung Transplant 2003;22:1082- 90.
  369. Braith RW, Welsch MA, Mills RM Jr, Keller JW, Pollock ML. Resistance exercise prevents glucocorticoid-induced myopathy in heart transplant recipients. Med Sci Sports Exerc 1998;30:483-9.
  370. White-Williams C, Jalowiec A, Grady K. Who returns to work after heart transplantation? J Heart Lung Transplant 2005; 24:2255-61.
  371. Волкова О.В. Социальная реабилитация как направление социальной работы. Психолого-педагогический журнал Гаудеамус. 2006. Т. 2. № 10. С. 171-177.
  372. Fusar-Poli P, Picchioni M, Martinelli V, et al. Anti-depressive therapies after heart transplantation. J Heart Lung Transplant 2006; 25: 785-93.
  373. Dew MA, DiMartini AF, De Vito DA, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ trans- plantation. Transplantation 2007;83:858-73.
  374. Havik OE, Sivertsen B, Relbo A, et al. Depressive symptoms and all-cause mortality after heart transplantation. Transplantation 2007; 84:97-103.
  375. Lawrence K, Stilley CS, Olshansky E, Bender A, Webber SA. Further exploration: maturity and adherence in adolescent and young adult heart transplant recipients. Prog Transplant 2008;18:50-4.
  376. De Bleser L, Matteson M, Dobbels F, Russell C, De GS. Interventions to improve medication-adherence after transplantation: a systematic review. Transpl Int 2009;22:780-97.
  377. Wray J, Waters S, Radley-Smith R, Sensky T. Adherence in adolescents and young adults following heart or heart-lung transplantation. Pediatr Transplant 2006;10:694-700.
  378. Coscia LA, Constantinescu S, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2007; 29-42.
  379. Sibanda N, Briggs JD, Davison JM, Johnson RJ, Rudge CJ. Pregnancy after organ transplantation: a report from the UK Transplant pregnancy registry. Transplantation 2007; 83: 1301-7.
  380. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89.
  381. Estes CM, Westhoff C. Contraception for the transplant patient. Se- min Perinatol 2007;31:372-7.
  382. Sucato GS, Murray PJ. Gynecologic health care for the adolescent solid organ transplant recipient. Pediatr Transplant 2005; 9: 346-56.
  383. McKay DB, Josephson MA, Armenti VT, et al. Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant 2005; 5: 1592-9.
  384. Schofield RS, Edwards DG, Schuler BT, et al. Vascular effects of sildenafil in hypertensive cardiac transplant recipients. Am J Hypertens 2003;16: 874-7.
  385. Halinen MO, Jaussi A. Fatal road accidents caused by sudden death of the driver in Finland and Vaud, Switzerland. Eur Heart J 1994; 15: 888-94.
  386. Ostrom M, Eriksson A. Natural death while driving. J Forensic Sci. 1987;32: 988- 98.
  387. McFarland RA, Moore RC. Accidents and accident prevention. In Annual Review of Medicine Vol. 13. ed. Rystand DA, Creger WP. Palo Alto CA. Annual Reviews, Inc. 1962.
  388. Petch MC. Task Force Report. Driving and heart disease. Eur Heart J. 1998;19:1165-1177.
  389. Petch M, Irvine J. Cardiovascular disorders and vocational driving. The Practitioner. 1995;239:37-39.
  390. Miles W. Driving issues related to arrhythmic syncope. Cardiol. Clinics. 1997;15: 327-39.
  391. Australasian Faculty of Occupational Medicine. Medical examinations of commercial vehicle drivers. National Road Transport Commission and the Federal Office of Road Safety. April 1997.
  392. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trend and disparities in coronary heart disease, stroke and other cardiovascular diseases in the United States: Findings of the National Conference on Cardiovascular Disease Prevention. Circulation. 2000;102:3137-47.
  393. Cupples LA, Gaglon DR, Kannel WB. Long and short term risks of coronary death. Circulation. 1992;85(Supplement 1):11-18.
  394. Tsunoda SM, Aweeka FT. Drug concentration monitoring of immunosuppressive agents: focus on tacrolimus, mycophenolate mofetil and sirolimus. BioDrugs 2000;14:355-69.
  395. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008;85:1675-85.
  396. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003;22: 58-69.
  397. Шевченко А.О.  Гиполипидемическая терапия у реципиентов сердца: статины. Вестник трансплантологии и искусственных органов 2016; Том XVIII. – № 2. – С 171-176.
  398. Randhawa P, Brennan DC. BK virus infection in transplant recipients: an overview and update. Am J Transplant 2006; 6: 2000-5.
  399. Kubak BM, Gregson AL, Pegues DA, et al. Use of hearts transplanted from donors with severe sepsis and infectious deaths. J Heart Lung Transplant 2009; 28:260-5.
  400. Crespo-Leiro MG, onso-Pulpon L, Vazquez de Prada JA, et al. Malignancy after heart transplantation: incidence, prognosis and risk factors. Am J Transplant 2008;8 : 1031-9.
  401. O"Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 1186-91.
  402. Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J Heart Lung Transplant 2007; 26: 557-64.
  403. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet 2006; 367: 233-9.
  404. Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant 2006;6:671-9.
  405. Wilkinson AH, Cohen DJ. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 1999;10:1136-44.
  406. Ojo AO. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol 2007; 27: 498-507.
  407. Поз Я.Л., Строков А.Г., Попцов В.Н., Копылова Ю.В., Крышин К.Н. Повреждение почек и заместительная почечная терапия у реципиента сердечного трансплантата. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № 1. С. 52-56.
  408. Raichin E, Kushwaha SS, Daly RC et al. Combined heart and kidney transplantation provides excellent survival and decreased risk of cellular rejection and coronary allograft vasculopathy. Transplant Proc. 2011; 43: 1871- 1776.
  409. Trachiotis GD, Vega JD, Jonhnston TS et al. Ten-year follow-up in patients with combined heart and kidney transplantation. J Thorac Cardiovasc Surg. 2003; 123: 2065-2071.
  410. Gill J, Shah T, Hristea I et al. Outcomes of simultaneous heart-kidney transplant in the US: a retrospective analysis using OPTN/UNOS data. Am J Transplant. 2009; 9: 844-852.
  411. Шевченко А.О., Никитина Е.А., Можейко Н.П., Тюняева И.Ю., Колоскова Н.Н. Распространенность и предикторы артериальной гипертонии у реципиентов сердца. Вестник трансплантологии и искусственных органов. 2017;        Том XIX. – № 3. – С. 33-39.
  412. Шевченко А.О., Тюняева И.Ю., Никитина Е.А., Орлов В.И. Назначение ингибиторов ангиотензинпревращающего фермента улучшает прогноз у реципиентов сердца с гипертрофией миокарда сердечного трансплантата. Вестник трансплантологии и искусственных органов. 2017 Т. XIX. – С. 85.
  413. Калинина А.М., Бойцов С.А., Кушунина Д.В., Горный Б.Э., Дроздова Л.Ю., Егоров В.А. Артериальная гипертензия в реальной практике здравоохранения: что показывают результаты диспансеризации. Артериальная гипертензия. 2017. Т. 23. № 1. С. 6-16.
  414. van de Beek D, Kremers W, Daly RC, et al. Effect of neurologic complications on outcome after heart transplant. Arch Neurol 2008; 65:226-31.
  415. Zierer A, Melby SJ, Voeller RK, et al. Significance of neurologic complications in the modern era of cardiac transplantation. Ann Thorac Surg 2007;83:1684-90.
  416. Mayer TO, Biller J, O’Donnell J, Meschia JF, Sokol DK. Contrasting the neurologic complications of cardiac transplantation in adults and children. J Child Neurol 2002;17:195-9.
  417. Marchetti P. New-onset diabetes after transplantation. J Heart Lung Transplant 2004;23(5 suppl):S194-201
  418. Hathout EH, Chinnock RE, Johnston JK, et al. Pediatric posttransplant diabetes: data from a large cohort of pediatric heart-transplant recipients. Am J Transplant 2003;3: 994-8.
  419. Pham PT, Pham PC, Lipshutz GS, Wilkinson AH. New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin North Am 2007;36: 873-90.
  420. Leidig-Bruckner G, Hosch S, Dodidou P, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001; 357:342-7.
  421. Kapetanakis EI, Antonopoulos AS, Antoniou TA, et al. Effect of long-term calcitonin administration on steroid-induced osteoporosis after cardiac transplantation. J Heart Lung Transplant 2005; 24: 526- 32.
  422. Pisani B, Mullen GM. Prevention of osteoporosis in cardiac transplant recipients. Curr Opin Cardiol 2002;17:160-4.
  423. Guo CY, Johnson A, Locke TJ, Eastell R. Mechanisms of bone loss after cardiac transplantation. Bone 1998; 22:267-71.
  424. Shane E, Addesso V, Namerow PB, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004; 350:767-76.
  425. Braith RW, Magyari PM, Fulton MN, et al. Comparison of calcitonin versus calcitonin plus resistance exercise as prophylaxis for osteoporosis in heart transplant recipients. Transplantation 2006;81:1191-5.
  426. Van Cleemput J, Daenen W, Geusens P,et al. Prevention of boneloss in cardiac transplant recipients. A comparison of biphosphonates and vitamin D. Transplantation 1996;61:1495-9.
  427. Cohen A, Addesso V, McMahon DJ, et al. Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover. Transplantation 2006; 81:686-91.
  428. Готье С.В., Хомяков С.М. Донорство и трансплантация органов в Российской Федерации в 2017 году X сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2018. Т. 20. № 2. С. 6-28.
  429. Готье С.В. Инновации в трансплантологии: развитие программы трансплантации сердца в Российской Федерации. Патология кровообращения и кардиохирургия. 2017. Т. 21. № 3S. С. 61-68.
  430. Готье С.В., Хомяков С.М. Донорство и трансплантация органов в Российской Федерации в 2016 году IX сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № 2. С. 6-26.
  431. Готье С.В., Хомяков С.М. Совершенствование нормативно-правовой базы в области донорства и трансплантации органов и тканей человека на уровне субъекта Российской Федерации. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № S. С. 8-9.
  432. Готье С.В., Шевченко А.О., Саитгареев Р.Ш., Захаревич В.М., Попцов В.Н., Зубкова Е.А., Донцов В.В. Сравнительный анализ краткосрочного и отдаленного прогноза выживаемости реципиентов трансплантированного сердца, оперированных в разные годы. Вестник трансплантологии и искусственных органов. 2016. Т. 18. № S. С. 26-27.
  433. Lund LH et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report – 2016. The Journal of Heart and Lung Transplantation. 2016; 35 (10): 1158– 1169.
  434. Готье СВ, Шевченко АО, Попцов ВН. Пациент с трансплантированным сердцем (ISBN: 978-5-94789- 648-0). М.–Тверь: Триада, 2014: 144. Gautier SV, Shev­chenko AO, Poptsov VN. Patsient s transplantirovannym serdtsem (ISBN: 978-5-94789-648-0). M.–Tver: Triada, 2014: 144
  435. Cousino MK, Miller VA, Smith C, Uzark K, Lowery R, Rottach N, Blume ED, Schumacher KR. Medical and end-of-life decision making in adolescents" pre-heart transplant: A descriptive pilot study. Palliat Med. 2020 Mar;34(3):272-280. doi: 10.1177/0269216319874689
  436. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29:914.
  437. Pollesello P, Parissis J, Kivikko M, Harjola VP. Levosimendan meta-analyses: is there a pattern in the effect on mortality? Int J Cardiol 2016;209:77-83
  438. Landoni G, Mizzi A, Biondi-Zoccai G, et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 2010;24:51-57
  439. Harrison RW, Hasselblad V, Mehta RH, Levin R, Harrington RA, Alexander JH. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2013;27:1224-1232
  440. Mehta RH, Leimberger JD, van Diepen S, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med 2017;376:2032-2042
  441. Landoni G, Lomivorotov VV, Alvaro G, et al. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med 2017;376:2021-2031
  442. Papp Z, Édes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol2012;159:82-87
  443. Zipfel S, Reiter B, Barten M, Rybczinski M, Schrage B, Westermann D, et al. Levosimendan effects benefit weaning from veno-arterial extracorporeal life support. J Heart Lung Transplant. 2018;37:S383.
  444. Schumann J, Henrich EC, Strobl H, Prondzinsky R, Weiche S, Thiele H, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2018;1:CD009669.
  445. Scheeren T.W.L. et al. Current use of inotropes in circulatory shock. Ann. Intensive Care. 2021; 11:21 https://doi.org/10.1186/s13613-021-00806-8
  446. Bart Hiemstra, Geert Koster, Jørn Wetterslev, Christian Gluud, Janus C. Jakobsen, Thomas W. L. Scheeren, Frederik Keus, Iwan C. C. van der Horst. Dopamine in critically ill patients with cardiac dysfunction: A systematic review with meta-analysis and trial sequential analysis. Acta Anaesthesiologica Scandinavica. 2019; 63(4): 424-437.
  447. De Backer D et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. N Engl J Med 2010; 362:779-789
  448. Simsch O. et al. The intensive care management of patients following heart transplantation at the Deutsches Herzzentrum Berlin.  Applied Cardiopulmonary Pathophysiology. 2011; 15: 230-240
  449. Freeman R. et al. Cardiac Transplant Postoperative Management and Care. Critical Care Nursing Quarterly. 2016; 39(3): 214-226. doi: 10.1097/CNQ.0000000000000116
  450. Higgins R, Kirklin JK, Brown RN, et al. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? J Heart Lung Transplant 2005; 24:392.
  451. Rosenberg PB, Vriesendorp AE, Drazner MH, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant. 2005;24(9):1327. 
  452. Yamani MH, Taylor DO, Czerr J, et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transplant 2008; 22:76.
  453. Cantarovich M, Giannetti N, Barkun J, Cecere R. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation 2004; 78:779.
  454. Anselm A., Cantarovich M., Davies R., et al. Prolonged basiliximab use as an alternative to calcineurin inhibition to allow renal recovery late after heart transplantation. J Heart Lung Transplant. 2008; 27: 1043-1045
  455. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. J Heart Lung Transplant 2019; 38:1056.
  456. Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 2008; 86:947.
  457. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67:1011.
  458. El-Hamamsy I, Stevens LM, Carrier M, et al. Incidence and prognosis of cancer following heart transplantation using RATG induction therapy. Transpl Int 2005; 18:1280.
  459. Carrier M, Leblanc MH, Perrault LP, et al. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant 2007; 26:258.
  460. Ansari D. et al. Comparison of Basiliximab and Anti‐Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis. J Am Heart Assoc. 2016;5:e002790. https://doi.org/10.1161/JAHA.115.002790
  461. Ansari D., Lund L.H., Stehlik J., et al. Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab. Journal of Heart and Lung Transplantation. 2015; 34 (10): 1283-1291.
  462. Amin A.A., Araj F.G., Ariyamuthu, et al. Impact of induction immunosuppression on patient survival in heart transplant recipients treated with tacrolimus and mycophenolic acid in the current allocation era. Clinical Transplantation. 2019; 33 (8): e13651
  463. Tzani A., Van den Eynde J., Doulamis I.P.,  et al. Impact of induction therapy on outcomes after heart transplantation. Clinical Transplantation. 2021; 35 (10): e14440
  464. Mehra M.R., Zucker M.J., Wagoner L., et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant. 2005; 24: 1297-1304
  465. Chou N.K., Wang S.S., Chen Y.S., et al. Induction Immunosuppression With Basiliximab in Heart Transplantation. Transplantation Proceedings. 2008; 40 (8): 2623-2625.
  466. Mattei M.F. et al.  Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant. 2007;26(7):693-9. doi: 10.1016/j.healun.2007.05.002.
  467. Kittipibul V., Tantrachoti P., Ongcharit P., et al. Low-dose basiliximab induction therapy in heart transplantation. Clinical Transplantation 2017; 31 (12): e13132
  468. Briasoulis A., Inampudi C., Pala, M., et al. Induction immunosuppressive therapy in cardiac transplantation: a systematic review and meta-analysis. Heart Failure Reviews. 2018; 23 (5): 641-649.
  469. Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006; 25:434.
  470. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66:507.
  471. Kobashigawa JA, Renlund DG, Gerosa G, et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 2006; 25:935
  472. Lehmkuhl H, Hummel M, Kobashigawa J, et al. Enteric-coated mycophenolate-sodium in heart transplantation: efficacy, safety, and pharmacokinetic compared with mycophenolate mofetil. Transplant Proc 2008; 40:953.
  473. Cohen DJ. Action, efficacy and toxicities: corticosteroids. In: Norman DJ, Turka LA, eds. Primer on Transplantation. Mt Laurel, NJ: American Society of Transplantation; 2001: 146–151.
  474. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995; 270: 286–290.
  475. Hosenpud JD, Norman DJ, Pantely GA. Low-dose oral prednisone in the treatment of acute cardiac allograft rejection not associated with hemodynamic compromise. J Heart Transplant. 1990; 9: 292–296
  476. Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006; 6:986.
  477. González-Vílchez F, de Prada JA, Exposito V, et al. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. J Heart Lung Transplant 2008; 27:1135.
  478. Eisen HJ, Kobashigawa J, Starling RC, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 2013; 13:1203.
  479. Andreassen AK, Andersson B, Gustafsson F, et al. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant 2014; 14:1828.
  480. Готье С.В., Хомяков С.М. Донорство и трансплантация органов в Российской Федерации в 2020 году XIII сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2021;23(3):8-34. https://doi.org/10.15825/1995-1191-2021-3-8-34
  481. Ueyama H. et al. Maintenance immunosuppression in heart transplantation: insights from network meta-analysis of various immunosuppression regimens //Heart Failure Reviews. – 2020. – С. 1-9.
  482. Castel M. A. et al. Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine //Transplantation proceedings. – Elsevier, 2011. – Т. 43. – №. 6. – С. 2244-2246.
  483. Nassetta K. et al. A Systematic Review of Adherence to Immunosuppression among Pediatric Heart Transplant Patients //Journal of Cardiovascular Development and Disease. – 2022. – Т. 9. – №. 5. – С. 165.
  484. Briasoulis A. et al. Induction immunosuppressive therapy in cardiac transplantation: a systematic review and meta-analysis //Heart Failure Reviews. – 2018. – Т. 23. – №. 5. – С. 641-649.
  485. Segovia J. et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study //Transplantation. – 2006. – Т. 81. – №. 11. – С. 1542-1548.
  486. Ford K. A. et al. Initial data on basiliximab in critically ill children undergoing heart transplantation //The Journal of heart and lung transplantation. – 2005. – Т. 24. – №. 9. – С. 1284-1288.
  487. Butts R. J. et al. Comparison of basiliximab vs antithymocyte globulin for induction in pediatric heart transplant recipients: an analysis of the International Society for Heart and Lung Transplantation database //Pediatric Transplantation. – 2018. – Т. 22. – №. 4. – С. e13190.
  488. Dipchand A. I. et al. Mycophenolate mofetil in pediatric heart transplant recipients: a single‐center experience //Pediatric transplantation. – 2001. – Т. 5. – №. 2. – С. 112-118.
  489. Crowley K. L., Webber S. Immunosuppressive Agents in Pediatric Heart Transplantation //Handbook of Pediatric Cardiovascular Drugs. – Springer, London, 2014. – С. 329-363.
  490. Sigfússon G. et al. Long-term survivors of pediatric heart transplantation: a multicenter report of sixty-eight children who have survived longer than five years //The Journal of pediatrics. – 1997. – Т. 130. – №. 6. – С. 862-871.
  491. Baraldo M., Gregoraci G., Livi U. Steroid‐free and steroid withdrawal protocols in heart transplantation: the review of literature //Transplant International. – 2014. – Т. 27. – №. 6. – С. 515-529.
  492. Backer C. L. et al. Intermediate term results of infant orthotopic cardiac transplantation from two centers //The Journal of Thoracic and Cardiovascular Surgery. – 1991. – Т. 101. – №. 5. – С. 826-832.
  493. Rider A. K. et al. The status of cardiac transplantation, 1975 //Circulation. – 1975. – Т. 52. – №. 4. – С. 531-539.
  494. Taylor D. O. et al. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy //The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. – 1996. – Т. 15. – №. 10. – С. 1039-1046.
  495. Opelz G. et al. Long‐term prospective study of steroid withdrawal in kidney and heart transplant recipients //American Journal of Transplantation. – 2005. – Т. 5. – №. 4. – С. 720-728.
  496. Felkel T. O. et al. Survival and incidence of acute rejection in heart transplant recipients undergoing successful withdrawal from steroid therapy //The Journal of heart and lung transplantation. – 2002. – Т. 21. – №. 5. – С. 530-539.
  497. Hunt J. et al. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation //The Journal of heart and lung transplantation. – 2005. – Т. 24. – №. 11. – С. 1863-1867.
  498. Crowley K. L., Webber S. Immunosuppressive Agents in Pediatric Heart Transplantation //Handbook of Pediatric Cardiovascular Drugs. – Springer, London, 2014. – С. 329-363.
  499. Bansal N. et al. Clinical approach to acute cellular rejection from the pediatric heart transplant society //Pediatric Transplantation. – 2022. – Т. 26. – №. 8. – С. e14393.
  500. Chan J. B. et al. Cellular rejection of the conduction system after orthotopic heart transplantation for congenital atrioventricular block //The Journal of heart and lung transplantation. – 2006. – Т. 25. – №. 11. – С. 1371-1375.
  501. Fabrizio C. et al. Treatment of Anti-Body Mediated Rejection Complicated by Cardiogenic Shock with a Temporary Left Ventricular Assist Device as a Bridge to Recovery //The Journal of Heart and Lung Transplantation. – 2021. – Т. 40. – №. 4. – С. S533.
  502. Ciliberto G. R. et al. Acute rejection after heart transplantation: noninvasive echocardiographic evaluation //Journal of the American College of Cardiology. – 1994. – Т. 23. – №. 5. – С. 1156-1161.
  503. Dearani J. A. et al. Pediatric cardiac retransplantation: intermediate-term results //The Annals of thoracic surgery. – 2001. – Т. 71. – №. 1. – С. 66-70.
  504. Uber W. E. et al. Acute antibody‐mediated rejection following heart transplantation //American Journal of Transplantation. – 2007. – Т. 7. – №. 9. – С. 2064-2074.
  505. Briasoulis A. et al. Induction immunosuppressive therapy in cardiac transplantation: a systematic review and meta-analysis //Heart Failure Reviews. – 2018. – Т. 23. – №. 5. – С. 641-649.
  506. Ford K. A. et al. Initial data on basiliximab in critically ill children undergoing heart transplantation //The Journal of heart and lung transplantation. – 2005. – Т. 24. – №. 9. – С. 1284-1288.
  507. Butts R. J. et al. Comparison of basiliximab vs antithymocyte globulin for induction in pediatric heart transplant recipients: an analysis of the International Society for Heart and Lung Transplantation database //Pediatric Transplantation. – 2018. – Т. 22. – №. 4. – С. e13190.
  508. Gullestad L. et al. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial //Transplantation. – 2010. – Т. 90. – №. 12. – С. 1581-1589.09/
  509. Minghelli G. et al. Uricosuric effect of the angiotensin ii receptor antagonist losartan in heart transplant recipients1 //Transplantation. – 1998. – Т. 66. – №. 2. – С. 268-271.
  510. Weinrauch L. A., D"Elia J. A. Use of calcium channel blockers after heart transplantation //The American Journal of Cardiology. – 2017. – Т. 120. – №. 3. – С. 512.
  511. Lobach N. E. et al. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience //The Journal of heart and lung transplantation. – 2005. – Т. 24. – №. 2. – С. 184-189.
  512. Irving C. A., Webber S. A. Immunosuppression therapy for pediatric heart transplantation //Current treatment options in cardiovascular medicine. – 2010. – Т. 12. – №. 5. – С. 489-502.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*